Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) was upgraded by equities researchers at D. Boral Capital from a “hold” ...

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an ...

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a biopharmaceutical company specializing in critical care products, unveiled its financial results for the fiscal full year ending September 30, 2024. The ...

Citius Pharma ( (CTXR) ) has released its Q4 earnings. Here is a breakdown of the information Citius Pharma presented to its investors.Don't ...

Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024, following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, ...

PitchBook’s VC-Backed IPO Index is up 68% through Dec. 27 and at its highest level in three years. We sell different types of products and services to both investment professionals and ...